New systemic antifungal drugs: Mechanisms of action, drug interactions and side effects;Neue systemische antimykotika: Wirkungsmechanismen, Interaktionen, unerwünschte Wirkungen

Mycoses

Volumn 46, Issue SUPPL. 1, 2003, Pages 28-31

  Schäfer Korting, Monika ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Antifungol agents; Azole resistance; Caspofungin; Glucan synthesis inhibitors; Voriconazol

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN; CYCLOSPORIN; DIGOXIN; ERGOSTEROL; FLUCONAZOLE; GLUCAN SYNTHASE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; OMEPRAZOLE; PHENYTOIN; POSACONAZOLE; PREDNISOLONE; RAVUCONAZOLE; RIFABUTIN; RIFAMPICIN; TACROLIMUS; VORICONAZOLE; WARFARIN;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; CANDIDIASIS; CONFERENCE PAPER; DRUG CONTRAINDICATION; DRUG TOLERABILITY; HUMAN; IMMUNE DEFICIENCY; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL;

EID: 0037908844     PISSN: 09337407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2003.tb00034.x     Document Type: Conference Paper

References (17)

1. Ruhnke, M. (2003) Systemmykosen. Pharmazie in unserer Zeit, im Druck.
2. Löffler, J.S., Kelly, L., Hebart, H., Schumacher, U., Lass-Flörl, C. & Einsele, H. (1997) Molecular analytics of cys51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol. Lett. 151, 263-268.
3. Morschhäuser, J. (2003) Resistenzen und Resistenzmechanismen. Pharmazie in unserer Zeit, im Druck.
4. Schäfer-Korting, M. & Holzgrabe U. (2003) Neue Antimykotika. Pharmazie in unserer Zeit, im Druck.
5. Balkis, M. M., Leidlich, S. D., Mukherjee, P. K. & Ghannoum, M. A. (2002) Mechanisms of fungal resistance. Drugs 62, 1025-1040.
6. Chandrasekar, P.H. & Manavathu, E. (2001) Voriconazole a second-generation triazole. Drugs Today 37, 135-148.
7. Denning, D. W., Ribaud, P., Milpied, N. et al. (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34, 563-71.
8. Ally, R., Schürmann, D., Kreisel, W. et al. (2001) A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis 31, 1447-1454.
9. Hofman, H. L. & Rathbun, R. C. (2002) Review of the safety and efficacy of voriconazole. Expert Opinion Investig. Drugs 11, 409-429.
10. Lazarus, H. M., Blumer, J. L, Yanovich, S., Schlamm, H. & Romero, A. (2002) Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J. Clin. Pharmacol. 42, 395-402.
11. Romero, A. J., Le Pogamp, P., Nilsson, L.-G. & Wood, N. (2002) Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin. Pharmacol. Ther. 71, 226-234.
12. Sugar, A. M. & Liu, X.-P. (2000) Effect of grapefruit juice on serum voriconazol concentrations in the mouse. Med. Mycol. 38, 209-212.
13. Kurtz, M. B. (2000) New antifungal drug targets. A vision for the future. Am. Soc. Microbiol. News 64, 31-39.
14. Onishi, J., Meinz, M., Thompson, J. et al., Discovery of novel antifungal (1,3)-β-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. 44, 368-377.
15. Feldmesser, M., Kress, Y., Mednick, A. & Casadevall, A. (2000) The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J. Infect. Dis. 182, 1791-1795.
16. Balani, S. K., Xu, X., Arison, B. H. et al. (2000) Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab. Dispos. 28, 1274-1278.
17. Stone, J. A., Holland, S. D., Wickersham, P. J. et al. (2002) Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. 46, 739-745.